Bictegravir

Merck announced positive phase 3 trial results for doravirine/islatravir, a once-daily, oral, two-drug regimen for HIV-1, showing non-inferiority to current therapies. The company plans to present findings and file with regulators, continuing its commitment to advancing HIV treatment options.

Merck announced positive Phase 3 results for doravirine/islatravir in HIV-1 trials, showing non-inferiority to current therapies and consistent safety.

2024 HIV treatment guidelines emphasize simplification of ART regimens, including dolutegravir and bictegravir options for pregnancy and virologic failure. Long-acting cabotegravir/rilpivirine is highlighted for virologic suppression, though access remains limited. New sections address cancer and cardiovascular health, and updates include recommendations for latent tuberculosis and HIV prevention, stressing the need for equitable access to advanced treatments.

Gilead presents new HIV treatment data at HIV Glasgow 2024, highlighting Biktarvy's long-term efficacy and safety, and exploring novel regimens with varied dosing frequencies.

Gilead to present over 40 HIV research studies at HIV Glasgow 2024, including late-breaking data on lenacapavir for HIV prevention and Biktarvy for HIV treatment, highlighting a robust portfolio and future-looking pipeline focused on person-centered drug development strategies.

Gilead Sciences reported Q3 2024 revenue growth of 7% to $7.5 billion, with Biktarvy sales up 13% to $3.5 billion. Oncology sales rose 6% to $816 million. The company increased its full-year revenue, operating income, and EPS guidance. Product sales excluding Veklury grew 7% to $6.8 billion, driven by higher sales in HIV, Oncology, and Liver Disease.

Gilead and MSD advance their once-weekly HIV treatment to Phase II trials after a 48-week study showed 94.2% of patients maintained viral loads below 50 copies m/L. The treatment combines MSD’s islatravir with Gilead’s lenacapavir, offering a long-acting alternative to daily HIV medications like Gilead’s Biktarvy.

Gilead and Merck presented Week 48 results from a phase 2 study evaluating a once-weekly oral combination of islatravir and lenacapavir for HIV-suppressed patients, showing comparable viral suppression rates to daily Biktarvy. The combination, not yet approved, will advance to phase 3 trials.